We are joined by our Editor-in-Chief for European Oncology & Haematology, Axel S Merseburger, to discuss the recent results of the OLYMPUS trial, an ongoing, single-arm, multicenter trial enrolling 71 patients with treatment-naïve or recurrent low-grade non-invasive UTUC with at least one measurable papillary tumor located above the ureteropelvic junction.
For further information on this trial, please follow the following links
1. Before the approval of mitomycin pyelocalyceal, how was low-grade upper tract urothelial cancer treated, and what are the treatment challenges associated with the upper urinary tract? (0:06)
2. How is the gel administered and what is the treatment regimen? (0:52)
3. Could you tell us about the aims, design and inclusion criteria of the OLYMPUS trial? (1:56)
4. What were the major efficacy and safety findings of this trial? (3:16)
5. What patients are most likely to benefit from this therapy and how might it impact the future of urothelial cancer? (4:10)
Axel S Merseburger has no conflicts of interest to declare in relation to this video.
Commissioned, edited and funded by Touch Medical Media
Published: 14 May 2020
Share this Video
Related Videos In Genitourinary Cancers
Ajjai Alva, ESMO 2020 – Pembrolizumab plus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma: the KEYNOTE-361 trial
Dr Ajjai Alva discusses the rationale of pembrolizumab in combination with chemotherapy for the treatment of advanced urothelial cancer and findings from the KEYNOTE-361, and future directions for pembrolizumab research. The late-breaking abstract ‘Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361’ (LBA23) was presented […]
Yann-Alexandre Vano, ESMO 2020 – Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naive Metastatic Kidney Cancer: The BIONIKK Trial
Dr Yann-Alexandre Vano joins touchONCOLOGY to discuss the role of personalization of treatment in kidney cancer, and the major findings from the BIONIKK trial investigating nivolumab and ipilimumab as a first-line therapy for patients with kidney cancer. The late-breaking abstract ‘Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR […]
Thomas Powles, ASCO20: JAVELIN Bladder 100 Phase III Interim Analysis
It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma. Questions 1. What have we learned so far from clinical trials […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!